On the other hand, by binding to CXCR4 on tumour cells and stroma, plerixafor antagonises CXCR4 signalling, blockading chemokine-mediated immunosuppressive cell recruitment while augmenting immune infiltrates [11]. This evidence concerns the gene CXCR4 and neoplasm.